TNFRSF8 and neoplasm: Brentuximab vedotin (BV) is an anti-CD30 antibody attached to monomethyl auristatin E (MMAE), an antitubulin agent. The binding of BV to CD30 and its internalization will allow MMAE to exert its action and inhibit the assemblage of the microtubules, induce cell cycle arrest and cause cell death due to apoptosis of tumor cells [21,33].